- Home
- GILD vs TXN Comparison
GILD vs TXN Comparison
Compare GILD & TXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | TXN |
|---|---|---|
| Founded | 1987 | 1930 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9B | 160.9B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | GILD | TXN |
|---|---|---|
| Price | $141.36 | $196.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 22 |
| Target Price | $129.10 | ★ $202.76 |
| AVG Volume (30 Days) | 6.6M | ★ 6.6M |
| Earning Date | 02-10-2026 | 01-27-2026 |
| Dividend Yield | 2.29% | ★ 2.89% |
| EPS Growth | ★ 6514.05 | 2.06 |
| EPS | ★ 6.42 | 5.49 |
| Revenue | ★ $29,087,000,000.00 | $17,266,000,000.00 |
| Revenue This Year | $3.66 | $14.28 |
| Revenue Next Year | $3.32 | $8.26 |
| P/E Ratio | ★ $21.45 | $35.81 |
| Revenue Growth | 2.79 | ★ 9.90 |
| 52 Week Low | $93.10 | $139.95 |
| 52 Week High | $138.03 | $221.69 |
Technical Indicators
Market Signals| Indicator | GILD | TXN |
|---|---|---|
| Relative Strength Index (RSI) | 75.05 | 64.37 |
| Support Level | $120.95 | $191.13 |
| Resistance Level | $124.48 | $199.43 |
| Average True Range (ATR) | 4.14 | 4.74 |
| MACD | 1.99 | 0.42 |
| Stochastic Oscillator | 97.05 | 85.25 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.